Approaches to improve the pharmacokinetics of radiolabeled glucagon-like peptide-1 receptor ligands using antagonistic tracers

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1282-1288

  Rylova, Svetlana N ^a,b   Waser, Beatrice ^c   Pozzo, Luigi Del ^a,b   Tonnesmann, Roswitha ^b   Mansi, Rosalba ^b   Meyer, Philipp T ^b   Reubi, Jean Claude ^c   Maecke, Helmut R ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antagonist; GLP 1 receptor; Insulinoma; cell mass

Indexed keywords

BOLTON HUNTER REAGENT I 125; CHELATING AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LYSINE; NODAGA; TETRAXETAN; UNCLASSIFIED DRUG; 125I-BOLTON-HUNTER-EXENDIN(9-39); GLUCAGON LIKE PEPTIDE RECEPTOR; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG KIDNEY LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; IC50; IN VITRO STUDY; INSULINOMA; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; DRUG POTENTIATION; METABOLIC CLEARANCE RATE; NUDE MOUSE; PROCEDURES; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; DRUG SYNERGISM; FEMALE; GLUCAGON-LIKE PEPTIDE RECEPTORS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84982854603     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.168948     Document Type: Article

References (33)

1. Körner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743.
2. Reiner T, Thurber G, Gaglia J, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci USA. 2011;108:12815-12820.
3. Brand C, Abdel-Atti D, Zhang Y, et al. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjug Chem. 2014;25:1323-1330.
4. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
5. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
6. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabeled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging. 2012;7:160-166.
7. 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013;40:524-531.
8. 68Ga]exendin-4: a case report. J Clin Endocrinol Metab. 2014;99:1519-1524.
9. 64Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression. Theranostics. 2014;4:770-777.
10. 18F]exendin (9-39) as a potential biomarker to measure pancreatic beta-cell mass. Nucl Med Biol. 2012;39:167-176.
11. 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011;8:1775-1782.
12. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2012;39: 463-473.
13. 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake. Eur J Nucl Med Mol Imaging. 2015;42:531-532.
14. Vinet L, Lamprianou S, Babic A, et al. Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice. Diabetologia. 2015;58:304-312.
15. 68Ga-DOTA-Exendin-4 PET/CT: a pilot study. J Nucl Med. 2015;56:1075-1078.
16. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
17. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970-1978.
18. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist-from mice to men. Theranostics. 2014;4:412-419.
19. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221.
20. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650-19655.
21. Mukai E, Toyoda K, Kimura H, et al. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun. 2009; 389:523-526.
22. Waser B, Reubi JC. Radiolabeled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues. Eur J Nucl Med Mol Imaging. 2014;41:1166-1171.
23. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
24. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
25. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.
26. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004;145:667-678.
27. 68Ga-labeled [Nle(14), Lys (40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol. 2014;16:255-263.
28. Rylova SN, Barnucz E, Fani M, et al. Does imaging alphavbeta3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? J Nucl Med. 2014;55:1878-1884.
29. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110-1118.
30. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29:597-606.
31. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
32. 131I-BA52. J Nucl Med. 2014;55:9-14.
33. van Duijnhoven SM, Rossin R, van den Bosch SM, Wheatcroft MP, Hudson PJ, Robillard MS. Diabody pretargeting with click chemistry in vivo. J Nucl Med. 2015;56:1422-1428.